West Coast Financial LLC Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

West Coast Financial LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 143,213 shares of the medical research company’s stock after purchasing an additional 874 shares during the period. Edwards Lifesciences makes up about 1.0% of West Coast Financial LLC’s holdings, making the stock its 29th largest position. West Coast Financial LLC’s holdings in Edwards Lifesciences were worth $9,451,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in EW. Park Avenue Securities LLC lifted its stake in Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares during the last quarter. City State Bank lifted its stake in Edwards Lifesciences by 16.5% during the second quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after purchasing an additional 130 shares during the last quarter. Chapin Davis Inc. lifted its stake in Edwards Lifesciences by 1.7% during the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after purchasing an additional 140 shares during the last quarter. Valley National Advisers Inc. lifted its stake in Edwards Lifesciences by 6.0% during the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after purchasing an additional 152 shares during the last quarter. Finally, Choreo LLC lifted its stake in Edwards Lifesciences by 4.1% during the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock worth $367,000 after purchasing an additional 153 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EW. Canaccord Genuity Group dropped their target price on Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating on the stock in a research report on Monday. Citigroup dropped their target price on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, October 1st. Robert W. Baird lowered Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a research report on Thursday, July 25th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, Daiwa America raised Edwards Lifesciences to a “strong-buy” rating in a research report on Wednesday, July 31st. Seventeen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $75.77.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,250 shares of company stock valued at $751,688. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Up 0.8 %

NYSE EW traded up $0.55 during trading on Friday, reaching $68.81. 899,313 shares of the company’s stock were exchanged, compared to its average volume of 4,559,637. The firm has a market capitalization of $41.45 billion, a PE ratio of 28.09, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company’s fifty day simple moving average is $66.99 and its 200-day simple moving average is $80.35.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same period last year, the business earned $0.66 EPS. The firm’s revenue was up 6.7% compared to the same quarter last year. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.